Some argue the current system of subsidising drugs in Australia needs changing to accommodate new cancer therapies. But two recent drug listings show the current system is working perfectly well.
- Professor of Health Economics, Deputy Director of CHERE, University of Technology Sydney
The consultation paper by the panel of the McKeon Review is available and open for public comment now, so it’s worth examining whether this review (the latest of many into health and medical research…
Contact Marion for
- General
- Media request
- Speaking request
- Consulting / Advising
- Research collaboration
- Research supervision
- Location: Sydney, Australia
- Website
- Article Feed
- Joined
